Dickran Kazandjian

University of Miami
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

Purpose: Early intervention for high-risk smoldering multiple myeloma (HR-SMM) achieves deep and prolonged responses. It is unclear if beneficial outcomes are due to the treatment of less complex, susceptible disease or inaccuracy in clinical definition of cases entered. Experimental Design: In this study, we interrogated whole-genome and whole-exome sequencing for 54 patients across two HR-SMM interventional studies (NCT01572480 and NCT02279394). Results: We reveal that the genomic landscape of treated HR-SMM is generally simple as compared with newly diagnosed multiple myeloma counterparts with less inactivation of tumor suppressor genes, RAS pathway mutations, MYC disruption, and APOBEC contribution. The absence of these events parallels that of indolent precursor conditions, possibly explaining overall excellent outcomes. However, some patients harboring genomic complexity fail to sustain response and experience resistant, progressive disease. Overall, clinical risk scores do not effectively discriminate between genomically indolent and aggressive disease. Conclusions: Genomic profiling can contextualize the advantage of early intervention in SMM and guide personalization of therapy. See related commentary by Weinhold and Rasche, p. 4263

Year:

2024

Summary: In this issue, Paiva and colleagues characterize the dynamics of minimal residual disease (MRD) and clinical responses during chimeric antigen receptor (CAR) T-cell therapy of relapsed/refractory multiple myeloma. Although both correlate with prolonged progression-free survival, MRD is reached faster in the bone marrow than complete response in peripheral blood; consequently, the study addresses the need for future guidelines to explore new MRD-negative definitions that are independent of the monoclonal (M) protein to overcome this limitation, particularly in clinical trials using early depth of response as an endpoint. See related article by Paiva et al., p. 365 (1).

Year:

2023

Collaborators (7)

Ola Landgren

Professor of Medicine

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details

Bachisio Ziccheddu

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details

Irene Ghobrial

Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Saad Usmani

Chief Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Gad Getz

Broad Institute

UNITED STATES
View details

Francesco Maura

Assistant Professor

Sylvester Comprehensive Cancer Center

UNITED STATES
View details

Patrick Blaney

Senior Bioinformatics Programmer

NYU Langone Health

UNITED STATES
View details